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Cutaneous Human Papillomaviruses Persist on
Healthy Skin
Kristina Hazard1, Anna Karlsson1, Kristin Andersson1, Henrik Ekberg2, Joakim Dillner1 and Ola Forslund1
Cutaneous human papillomaviruses (HPVs) are frequently found in healthy skin and have also been implicated
in non-melanoma skin cancer. For genital HPV types, a persistent infection with one of the high-risk types is a
prerequisite for the development of cervical cancer. However, there is only limited data on whether infections
with cutaneous HPV types persist over time. Serial forehead swab samples collected from 63 volunteers
(42 healthy individuals and 31 renal transplant recipients (RTRs)), sampled 6.3 years (range: 5.0–7.0 years) apart,
were analyzed for HPV using general primer PCR, cloning, and sequencing. Among the healthy individuals, the
prevalences of HPV were 69% (29/42) at enrolment and 71% (30/42) at follow-up. Among the individuals positive
at baseline, 48% (14/29) had a persistent infection. Among the RTRs, 71% (15/21) were positive for HPV at
enrolment and 90% (19/21) at follow-up. A persistent infection was detected in 33% (5/15). In total, HPV was
detected in 44 of the samples collected at baseline and the same virus was found at follow-up in 43% (19/44).
Persistence was not significantly associated with age, sex, immunosuppressive treatment, history of warts, or
genus of HPV. We conclude that cutaneous HPV infections commonly persist over several years on healthy skin.
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INTRODUCTION
Over 100 human papillomavirus (HPV) types have been
completely sequenced (de Villiers et al., 2004). In addition,
sequence information from PCR amplimers (FA amplicons)
have identified about 100 additional cutaneous putative HPV
types (Forslund et al., 1999, 2004; Antonsson et al., 2000,
2003). Different HPVs infect either mucosal epithelium or the
skin. Persistent infection with one of the high-risk genital HPV
types, for example, HPV16 or HPV18, is a prerequisite for
the development of cervical cancer (Bosch et al., 2002).
Cutaneous HPV types have been implicated in non-melano-
ma skin cancer in patients suffering from the rare inherited
genetic disease epidermodysplasia verruciformis (Jablonska
and Majewski, 1994). These patients are highly susceptible to
infections with a subset of beta-papillomaviruses (Kremsdorf
et al., 1984). HPV DNA is also detectable in skin carcinomas
from both renal transplant recipients (RTRs) (Berkhout et al.,
1995; de Jong-Tieben et al., 1995; de Villiers et al., 1997) and
immunocompetent individuals (Harwood and Proby, 2002).
The role of HPV in these cancers remains to be elucidated,
although recent serological studies suggest an association
(Karagas et al., 2006).
Healthy skin harbors a large spectrum of different HPV
types (Antonsson et al., 2000, 2003), with more virus being
detected in forehead samples than in samples from other
body parts such as arms and thighs (Antonsson et al., 2000).
However, there is limited data on whether these infections
persist in the skin.
In this study, our aims were to explore whether HPV
infections of healthy skin are persistently present after a
lengthy time span and to explore whether healthy subjects
and RTRs have different degrees of viral persistence.
RESULTS
Overall, 71 different HPV types or putative types were
detected (36 gamma-papillomaviruses, 34 beta-papilloma-
viruses, and one lambda papillomavirus) (Table 1). The most
commonly detected viruses were HPV20, HPV12, and FA1.1
(detected in 11, eight, and seven samples, respectively)
(Table 1). Forty-two viruses were each detected only in a
single sample (Table 1).
Among the healthy subjects, the prevalences of HPV were
69% (29/42) in the samples from 1998/1999 and 71% (30/42)
in the follow-up samples from 2005. Of the 29 healthy
individuals (17 females and 12 males) that were positive for
HPV in their first sample, 48% (14/29) were positive for the
same HPV type/putative type also in the second sample.
Among the RTRs, 71% (15/21) were positive for HPV in
their first sample, and 90% (19/21) were positive at follow-
up. Among the 15 RTRs (seven women and eight men)
positive for HPV in the first sample, 33% (5/15) had a
persistent infection (Table 1).
Overall, 70% (44/63) of the subjects were positive for HPV
DNA in their first sample and a persistent HPV infection was
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detected in 43% (19/44) of them (Table 1). Most persistent
infections (15/19 (79%)) were beta-papillomavirus infections,
with HPV20 being the single most common type-specific
persistent infection (in 4/19 (21%) of cases) (Table 1).
Eighteen subjects were positive for HPV in both samples,
but with different types. Seven subjects were HPV positive at
enrolment, but negative at follow-up. Twelve subjects were
negative for HPV at enrolment but positive at follow-up
(Table 1), and seven subjects were negative for HPV at both
occasions.
Table 1. HPV types detected on healthy skin among healthy individuals and renal transplant recipients with
a persistent HPV infection (a) or with non-persistent infections (b)
(a) Subjects with persistent infection
Age at first First sample (1998/1999) Second sample (2005)
sample (years) Gender HPV type/putative type Genus HPV type/putative type Genus
36 F FA36 b FA36 b
33 F FA23.1 b FA23.1 b
40 M HPV21 b HPV21 b
33 F FA35 g FA35 g
71 F FA14 b FA14 b
47 F HPV80, HPV12 b, b HPV80 b
74 F HPV20, HPV17 b, b HPV20 b
59 F HPV20, FA26.2 b, b HPV20, FA149 b, b
51 F HPV12 b HPV12, FA67, FAIMVS14 b, g, b
56 F HPV20, FA44 b, g HPV20, HPV14D, HPV19 b, b, b
49 M FA148, FA51 g, b FA148 g
79 F HPV14D, FA26.2 b, b HPV14D b
38 M HPV20, FA116 b, b HPV20, FA23.1 b, b
47 F FA130, FA31 b, g FA130, FA20.2 b, g
611 M FA14 b FA14 b
551 M FA122.3, HPV5b b, b FA122.3, HPV12, FA158 b, b, b
531 M HPV8, FA68 b, g HPV8 b
471 F FA89, FA115 g, g FA89, FA81, FA7 g, g, b
601 F FA134, HPV47 g, b FA134, HPV80 g, b
(b) Subjects with non-persistent infection
HPV type or putative type
First sample (1998/1999) Genus: beta-papillomavirus: HPV8, HPV19, HPV202, HPV212, HPV242, HPV76, FA14,
FA25, FA26.2, FA37, FA51.2, FA70, FA119
Genus: gamma-papillomavirus: HPV4, HPV50, FA1.13, FA13, FA20.3, FA43, FA67, FA792,
FA145, FA153, FA154, FA155, FA157
Genus: lambda-papillomavirus: FA38
Second sample (2005) Genus: beta-papillomavirus: HPV5, HPV82, HPV124, HPV14D, HPV192, HPV20, HPV38b[FA125],
HPV47, HPV76, FA18, FA26.2, FA37, FA39, vs92-1
Genus: gamma-papillomavirus: HPV50, FA1.12, FA1.2, FA6.22, FA11, FA30, FA32, FA68, FA81,
FA87, FA91, FA106, FA150, FA151, FA152, FA155, FA156, FAIMVS15.12
F, female; HPV, human papillomavirus; M, male.
Persistent HPV types are shown in bold.
1Renal transplant recipients.
2Detected in two subjects.
3Detected in five subjects.
4Detected in four subjects.
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None of the covariates were significantly associated with
persistence (Table 2), but HPV isolates within the genus beta-
papillomavirus tended to persist more than HPV isolates
of the genus gamma-papillomavirus, 38% (15/39) and 15%
(4/26), respectively (Table 1). This tendency is not likely to be
attributable to possible different sensitivities for different
genera in the PCR detection system, as a large number of
gamma-papillomavirus isolates were detected (Table 1).
DISCUSSION
We report that cutaneous HPVs commonly persist for many
years on healthy skin, with about half (48%) of the healthy
individuals being positive for the same HPV type 6 years
later. Considering the immunosuppression of the RTRs and
the fact that these patients commonly develop skin lesions,
for example, squamous-cell carcinoma, with detectable HPV
DNA (Berkhout et al., 1995, 2000; de Villiers et al., 1997), it
was surprising that persistent HPV infections were not more
common in this group than in healthy individuals.
Lack of correlation between presence of warts and HPV
persistence may also seem surprising. However, none of the
patients had warts on the forehead, where the sample for
HPV testing was taken.
The rather high rates of persistence found are still bound to
be underestimates. HPV persistence in low copy numbers
could have been missed using our general primer PCR
system. Also, only three clones per sample were sequenced.
This would tend to detect the most abundant infections, again
leaving the possibility open that HPV persistence in low copy
numbers could have escaped detection.
Previous reports have indicated that the viral DNA
contained in virions seems to be more protected against
DNA degradation than the human cellular DNA on the skin
surface (Antonsson et al., 2003; Hazard et al., 2006), which
could have contributed to the high HPV prevalences found
also in quite old samples.
Previous studies of cutaneous HPV persistence had a mean
follow-up of only 3.2 years and studied only RTRs, not
healthy subjects (Berkhout et al., 2000). We report that a high
proportion of cutaneous HPV infections are persistently
present after even longer time spans and that neither
immunosuppression, nor any other investigated covariate,
was significantly associated with persistence.
Presence of HPV DNA on the skin could reflect infection,
but may also conceivably reflect skin surface contamination
of virions shed from productively infected skin at other body
sites or even from other subjects. Although repeated
contamination with exogenous HPV DNA of the same type
cannot be excluded as a reason for persistence, the simplest
explanation for the very long-lasting persistence found is that
there is an HPV infection at the sampled site and that a
noteworthy proportion of cutaneous HPV infections tend to
persist for many years.
In conclusion, the knowledge that viral persistence is
common in the natural history of cutaneous HPV infections is
of interest for understanding the biology of these viruses and
may be helpful in the continuing elucidation of their possible
role in human skin disorders.
MATERIALS AND METHODS
Forehead swab samples from RTRs attending the outpatient clinic of
nephrology of Malmo¨ University Hospital, Sweden, and sex- and
age-matched healthy controls were collected from 1998 to 1999
(Antonsson et al., 2000). In 2005, the subjects who were not
Table 2. Multivariate analysis of parameters affecting
a persistent infection of any HPV type
Subjects with
persistence/
total (%)
Crude OR
(95% CI)
Adjusted1 OR
(95% CI)
All subjects 19/44 (43)
Healthy 14/29 (48.3) 1.0 (referent) 1.0 (referent)
RTR 5/15 (33.3) 0.54 (0.12–2.30) 0.84 (0.12–5.74)
Sex
Female 13/24 (54.2) 1.0 (referent) 1.0 (referent)
Male 6/20 (30.0) 0.37 (0.09–1.48) 0.23 (0.03–1.16)
Age (years)
o44 5/14 (35.7) 1.0 (referent) 1.0 (referent)
45–54 6/15 (40.0) 1.19 (0.21–7.03) 0.56 (0.04–5.53)
455 8/15 (53.3) 2.01 (0.37–11.86) 0.94 (0.05–17.9)
Warts at any site
No 15/33 (45.5) 1.0 (referent) 1.0 (referent)
Yes 4/11 (36.4) 0.69 (0.12–3.37) 0.79 (0.09–6.97)
Previous skin cancer
No 18/42 (42.9) 1.0 (referent) 1.0 (referent)
Yes 1/2 (50.0) 1.33 (0.02–109) 2.98 (0.009–1,015)
Any previous cancer
No 17/39 (43.6) 1.0 (referent) 1.0 (referent)
Yes 2/5 (40.0) 0.87 (0.06–8.47) 0.31 (0.004–8.9)
Any allergy
No 14/30 (46.7) 1.0 (referent) 1.0 (referent)
Yes 5/14 (35.7) 0.64 (0.13–2.77) 0.42 (0.05–2.84)
Eczema
No 14/35 (40.0) 1.0 (referent) 1.0 (referent)
Yes 5/9 (55.6) 1.85 (0.33–11.1) 2.43 (0.35–20.3)
Genus of HPV
gamma 2/12 (16.7) 1.0 (referent) 1.0 (referent)
beta 12/20 (60.0) 7.02 (1.08–82.7) 5.94 (0.64–105)
gamma+beta 5/12 (41.7) 3.38 (0.40–45.4) 4.37 (0.33–97.5)
CI, confidence interval; HPV, human papillomavirus; OR, odds ratio;
RTR, renal transplant recipient.
Only patients positive for HPV in the first sample were included in the
analysis. Questions answered at collection of the first sample.
1Adjusted for all parameters in the table.
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deceased and had not emigrated were invited again. New forehead
swab samples could be collected from 21/31 of the invited RTRs
(10 females and 11 males, mean age 50 years at first sampling) and
from 42/61 of the invited healthy subjects (22 females and 20 males,
mean age 47 years). Mean follow-up time was 6.3 years (range:
5.0–7.0 years). Lund University Ethical Committee approved all
described studies. The study was conducted according to the Decla-
ration of Helsinki Principles, and all patients gave informed consent.
All subjects answered a questionnaire about presence/absence of
warts, eczema, allergy, and history of any cancer at both sampling
occasions. To avoid testing samples in any particular order, all
samples (collected 1998/1999 and 2005) and 12 internal controls
(NaCl) were given new randomized sample numbers and all
analyses were performed blinded to any information about the
samples.
HPV was detected by general primer PCR using FA primers
(Forslund et al., 1999), followed by cloning and sequencing of three
clones per sample.
Fifteen new HPV isolates (less than 98% identity to any known
HPV sequence) were detected in this study and submitted to Gen-
Bank with the following accession numbers: FA145 (DQ418463),
FA148 (DQ418464), FA149 (DQ418465), FA150 (DQ418466),
FA151 (DQ418467), FA152 (DQ418468), FA153 (DQ418469),
FA154 (DQ418470), FA155 (DQ418471), FA156 (DQ418472),
FA157 (DQ418473), FA158 (DQ418474), FA159 (DQ418475),
FA160 (DQ418476), and FA162 (DQ418477).
Multivariate analysis was performed using LogXact version 6
(Cytel, Cambridge, MA) with RTR/healthy, gender, age, presence/
absence of warts, history of cancer/skin cancer, allergy, eczema, and
genus of HPV included in the model. Questionnaire data from the
baseline visit were used.
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